App-Based study tracks quality of life in melanoma patients on targeted therapy
NCT ID NCT07022457
First seen Jun 24, 2026 · Last updated Jun 24, 2026
Summary
This study follows 50 adults in the UK with advanced BRAF V600 mutation-positive melanoma who are starting treatment with encorafenib and binimetinib. Instead of a controlled trial, it observes how these drugs work in real-world settings, focusing on patients' quality of life over 24 months. Participants use a smartphone app to report their well-being, while researchers also collect data from medical records.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC MELANOMA, BRAF V600 MUTATION POSITIVE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Addenbrookes Hospital
Cambridge, CB20QQ, United Kingdom
-
Queen Elizabeth Hospital
Birmingham, B152GW, United Kingdom
-
Royal Marsden Hospital
London, SW36JJ, United Kingdom
-
Royal Preston Hospital
Preston, PR26GP, United Kingdom
-
Southampton General Hospital
Southampton, SO166YD, United Kingdom
-
Southend University Hospital
Westcliff-on-Sea, Essex, SS00RY, United Kingdom
-
University Hospital Coventry and Warwickshire
Coventry, CV22DX, United Kingdom
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
encorafenib and binimetinib (targeted therapy combination)
What this could lead to
If successful, this study could provide real-world evidence on how these drugs affect quality of life in everyday practice, helping doctors and patients make more informed treatment decisions.
What could go wrong
This is an observational study with only 50 participants, so results may not apply to everyone. It does not test new treatments or compare them to alternatives, so no major breakthroughs are expected.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.